Evidence map›Paper›PMID 38302401›Full record

ArticleTrends in endocrinology and metabolism: TEM2024

Genetics unravels protein-metabolite relationships.

James R Hilser, Aldons J Lusis, Hooman Allayee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in endocrinology and metabolism: TEM, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

James R HilserDepartment of Population & Public Health Science, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Department of Biochemistry & Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Aldons J LusisDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Hooman AllayeeDepartment of Population & Public Health Science, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Department of Biochemistry & Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. Electronic address: hallayee@usc.edu.

Funding

The impact of estrogen receptor alpha on cardiomyocellular metabolism and healthU54HL170326 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Hooman Allayee · 2023 to 2026
$7.5M
Systems Genetics Dissection of Non-alcoholic SteatohepatitisR01DK117850 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Aldons Jake Lusis · 2019 to 2026
$4.6M
MECHANISMS UNDERLYING THE AGE-RELATED ATHEROPROTECTIVE EFFECTS OF HORMONE THERAPYR01AG059690 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HODIS, HOWARD NEIL · 2018 to 2022
$3.6M
Establishing mechanistic links between the gut microbiome and atherosclerosisR01HL148577 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI LUSIS, ALDONS JAKE, REY, FEDERICO E · 2020 to 2023
$2.6M
Gut microbiota and metabolite interactions in atherosclerosisR01HL144651 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE, REY, FEDERICO E · 2019 to 2022
$2.6M
Biological Mechanisms through which TMAO Promotes AtherosclerosisR01HL148110 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ALLAYEE, HOOMAN, SHIH, DIANA MOUHAN · 2020 to 2023
$2.5M
Genetic Predisposition to Myocardial Infarction in Patients with Coronary Artery DiseaseR01HL168493 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Hooman Allayee · 2024 to 2026
$2.2M
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitisR44DK136405 · NIDDK · MAX BIOPHARMA, INC. · PI PARHAMI, FARHAD · 2023 to 2024
$1.8M
NHLBI NIH HHS R01 HL144651NHLBI NIH HHS R01 HL148110NHLBI NIH HHS R01 HL148577NHLBI NIH HHS R01 HL168493NHLBI NIH HHS U54 HL170326NIA NIH HHS R01 AG059690NIDDK NIH HHS R01 DK117850NIDDK NIH HHS R44 DK136405
6 · The paper itself

Abstract

Integrating molecular traits into genetic studies enhances our understanding of how DNA variation influences complex clinical and physiological phenotypes. In a recent article, Benson and colleagues apply this systems genetics approach with proteomics and metabolomics data in plasma from humans to identify and validate several previously unrecognized causal protein-metabolite associations.

Indexed as

MetabolomicsProteomicsGenome-Wide Association StudyHumansPhenotypeMendelian randomizationmetabolomicsproteomicssystems genetics

Identifiers

PMID38302401
PMCPMC10939837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.